林业发展局小组拒绝UroGen的膀胱癌药物UGN-102,指出对效力的关切,导致库存下降。 FDA panel rejects UroGen's bladder cancer drug UGN-102, citing efficacy concerns, leading to stock decline.

UroGen Pharma的膀胱癌药物UGN-102在林业发展局的一个小组投票反对其批准后遭遇了挫折,原因是担心其效力,导致库存下降。 UroGen Pharma's bladder cancer drug, UGN-102, faced a setback after an FDA panel voted against its approval due to concerns about its efficacy, causing the stock to drop. 分析师Raghuram Selvaraju将库存从“Buy”降级为“Neutral”, Analyst Raghuram Selvaraju downgraded the stock from "Buy" to "Neutral," though he may reassess if the drug gets approval with conditions. UroGen有足够的资金运作到2026年底,其下一个药物UGN-103的第三阶段试验预计到2025年中期完成。 UroGen has sufficient funds to operate through late 2026, and the Phase 3 trial for its next drug, UGN-103, is expected to complete enrollment by mid-2025.